Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Johnson & Johnson (JNJ) vs Nerdwallet Inc (NRDS) Price & Performance

Johnson & JohnsonTrade
Nerdwallet IncTrade

Price performance (Past 24H)

Key statistics

Johnson & Johnson vs Nerdwallet Inc — how do they compare? Johnson & Johnson trades at $249.47 (market cap $598.96B), while Nerdwallet Inc trades at $8.93 (market cap $603.70M). The key difference: Johnson & Johnson is far larger — about 992.1× Nerdwallet Inc's market cap, and Johnson & Johnson pays a 2.15% dividend while Nerdwallet Inc pays none. Which is the better fit depends on your goals.

JNJNRDS
Market Cap
$598.96B$603.70M
Volume
6,156,228
Sector
HealthFinancials
52-Week High
$267.24$15.93
52-Week Low
$164.36$7.58
Enterprise Value
$631.90B$518.00M
Dividend Yield
2.15%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Johnson & Johnson

Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.

The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.

Nerdwallet Inc

NerdWallet (NRDS) trades at $9.17, down 0.97% with a bearish technical signal. The company demonstrates strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $0.29 versus $0.25 expected. Revenue grew to $836.6M in 2025 with improving net margins from -1.9% in 2022 to 5.82%. Valuation metrics appear attractive with P/E of 9.96 and P/S of 0.81. Recent news highlights the company's pivot to higher-margin transactions and launch of financial resilience indices.

The stock presents a compelling value opportunity with 39% upside to the $12.75 consensus target. Strong profitability metrics (93% gross margin, 19.47% ROE) and positive cash flow trends support the bullish case. Key risks include search-driven revenue headwinds and competitive pressures in financial guidance markets. Analyst consensus leans bullish with 4 buy ratings versus 1 hold and 1 sell.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Johnson & Johnson

Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.

Read more on JNJ

About Nerdwallet Inc

Nerdwallet Inc is a free tool to find you the best credit cards, cd rates, savings, checking accounts, scholarships, healthcare and airlines.

Read more on NRDS